FIGURE

Fig. 2

ID
ZDB-FIG-180711-14
Publication
McMacken et al., 2018 - The Beta-Adrenergic Agonist Salbutamol Modulates Neuromuscular Junction Formation in Zebrafish Models of Human Myasthenic Syndromes
Other Figures
All Figure Page
Back to All Figure Page
Fig. 2

Salbutamol treatment of Dok-7 MO-injected zebrafish improves NMJ morphology. Lateral views of 48 hpf embryos with neuromuscular synapses labelled with antibodies against SV2 (green, presynaptic vesicles) and αBTX (red, postsynaptic AChRs). Scale bar = 50 µm. (A) In Dok7 MO-injected embryos, the focal innervation point along the horizontal myoseptum is reduced in size compared with wild type, but is increased following treatment with 20 µm salbutamol (arrows). In addition, the morphology of myoseptal (boxes) and myotomal (asterisks) AChR clusters is partially rescued with salbutamol treatment. A representative 20 μm2 AChR cluster is labelled with a bracket. (B) Following salbutamol treatment, the area of synaptic contact on the horizontal myoseptum is significantly increased (** indicates P < 0.01, Student’s t-test, n = 160 treated and 160 untreated myotomal segments examined). (C) Salbutamol treatment caused a significant increase in the number of AChR clusters >20 μm2 per myotome in Dok7 zebrafish embryos (**** indicates P < 0.0001, Student’s t-test, n = 100 treated and 100 untreated myotomal segments examined).

Expression Data

Expression Detail
Antibody Labeling
Phenotype Data
Fish:
Condition:
Knockdown Reagent:
Observed In:
Stage: Long-pec

Phenotype Detail
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Hum. Mol. Genet.